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Abstract: Tuberculosis (TB) remains a significant cause of death worldwide, and emergence of 
drug-resistant TB requires lengthy treatments with toxic drugs that are less effective than their 
first-line equivalents. New treatments are urgently needed. Delamanid, previously OPC-67863, 
is a novel drug of the dihydro-nitroimidazole class with potent anti-TB activity and great prom-
ise to be effective in the treatment of drug-resistant TB. This review examines the preclinical 
and clinical development of delamanid, reviews current guidance on its use and evaluates the 
opportunities and challenges for its future role in TB management.
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Introduction
Tuberculosis (TB) remains a leading cause of morbidity and mortality worldwide. 
In 2013, an estimated 9 million people developed TB, with 1.5 million deaths; this 
is second only to the human immunodeficiency virus (HIV) as the leading infectious 
cause of death worldwide.1 The HIV epidemic continues to drive large numbers of 
new TB cases, particularly in sub-Saharan Africa.2 Combined HIV-TB management 
remains an important therapeutic challenge.
Effective 6-month combination treatment for TB using four first-line drugs 
(rifampicin, isoniazid, pyrazinamide, and ethambutol) has been available since the 
1980s.3 However, the magnitude of the global TB burden, particularly in low- and 
middle-income countries, continues to thwart effective disease control. Antibiotic 
resistance to Mycobacterium tuberculosis (Mtb) was identified in the 1940s4 and has 
expanded into a daunting clinical problem. Multidrug-resistant (MDR) TB is defined 
by resistance to both rifampicin and isoniazid. Although second-line drug regimens 
may be curative, treatment takes up to 2 years and medications are toxic and difficult 
to access.5 In 2013, 480,000 patients were diagnosed with MDR-TB but only 97,000 
patients initiated therapy.1 MDR-TB treatment success rates are often 50%. Since 
2006, extensively drug-resistant (XDR) TB, with additional resistance to injectable 
aminoglycosides and fluoroquinolones, has been described, with treatment success 
rates as low as 16%–22%.6–8 Since 2009, even more comprehensively resistant Mtb 
strains have been reported,9–12 generating fears that without new drugs, untreatable 
TB may reemerge in the 21st century.
The desired characteristics for new MDR-TB drugs and regimens have been 
clearly outlined; injectable agents should be replaced by all-oral regimens, therapy 
must be shorter, toxicity must be less, and drug-drug interactions (particularly with 
antiretroviral therapy [ART] for HIV) should be minimized.13,14
After a prolonged hiatus in the 1980s and 1990s, the last decade has seen the 
emergence of several new compounds from the drug development pipeline. In 2012, 
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the diarylquinoline ATP-synthase inhibitor, bedaquiline, was 
the first new anti-TB agent to be licensed since rifampicin 
in 1967.15 Two members of the dihydro-nitroimidazole class 
(delamanid [formerly OPC-67863] and pretomanid [formerly 
PA-824]) are also undergoing advanced clinical assessment. 
Delamanid has already been approved by the European 
Medicines Agency (EMA) and the Japanese Ministry of 
Health, Welfare and Labor (MHWL) for the treatment of 
MDR-TB.16 This article describes the preclinical and clinical 
development of delamanid, reviews current guidance on its 
use, and evaluates the opportunities and challenges for its 
future role in TB management.
Preclinical data
The best known drug from the nitroimidazole class is 
metronidazole, which is widely used for the treatment of 
anaerobic and protozoan infections but has potency against 
Mtb. In 1989, a related compound, the bicyclic nitroimidazole 
CGI-17341, was found to possess more favorable in vitro and 
in vivo antimycobacterial activity. However, it could not be 
developed further because of mutagenic properties.17,18 Two 
different research groups later developed the related com-
pounds PA-824 and OPC-67683 that were potent, orally bio-
available, and promising candidates for the treatment of TB. 
OPC-67683 was developed by Otsuka Pharmaceuticals and 
progressed to become delamanid. Table 1 summarizes the 
published preclinical studies for this compound.
Mechanism of action
Delamanid is thought to primarily inhibit synthesis of 
methoxy-mycolic and keto-mycolic acid, which are com-
ponents of the mycobacterial cell wall; unlike isoniazid, 
the drug does not inhibit alpha-mycolic acid.19,20 It has no 
action against gram-negative or gram-positive bacteria,16 
and this may be clinically advantageous as its restriction of 
use to mycobacterial infection may help prevent the genera-
tion of resistance. Like pretomanid, delamanid is a prodrug 
that requires metabolic activation for anti-TB activity to be 
exerted. Reactive intermediates in the metabolic pathway 
of the bicyclic nitroimidazoles may provide additional 
mechanisms of action, including interruption of cellular 
respiration.19,21 Activation of delamanid is thought to be medi-
ated via the mycobacterial F420 coenzyme system.20,22
Antimycobacterial potency
Delamanid has potent in vitro activity against both stan-
dardized and clinical Mtb isolates, with no cross-resistance 
to rifampicin, isoniazid, ethambutol, or streptomycin, and 
no antagonistic activity to these drugs.19,23,24 The minimum 
inhibitory concentrations (MIC) of delamanid ranges from 
Table 1 Published preclinical studies of delamanid
Year Author Study findings Reference
2005 Miyomoto* In vivo (mouse, rabbit, dog) assessment of PK profile 27
2006 Sasaki et al Synthesis of delamanid and demonstration of potent activity against Mtb 24
2006 Matsumoto et al in vitro delamanid lacks mutagenicity by BRM testing 19
2006 Matsumoto et al in vitro delamanid has potent activity against drug-susceptible Mtb and 
lack of cross-resistance with established drugs
19
2006 Matsumoto et al in vitro delamanid shows inhibitory effect on M. bovis mycolic acid 
biosynthesis suggesting that its acts at least in part by inhibiting 
mycobacterial cell wall formation
19
2006 Matsumoto et al in vitro delamanid has similar activity on intracellular M. tuberculosis in 
human macrophages as rifampicin
19
2006 Matsumoto et al in vivo (chronic Mtb murine model) delamanid shows potent activity as 
part of combination therapy
19
2006 Matsumoto et al in vitro (fresh human hepatocytes and microsomes) delamanid has no 
effect of cytochrome p450 enzymes
19
2006 Doi and 
Disratthakit*
in vitro delamanid is active against M. kansasii, and M. bovis but not  
M. avium, M. chelonae, M. abscessus, or M. fortuitum
25
2007 Saliu et al in vitro delamanid has potent sterilizing activity against Mtb in Bactec 
model
23
2012 Gurumurthy 
et al
Bicyclicnitroimidazoles are activated by deazaflavin (F420) dependent 
nitroreductase (Ddn) and drug resistance can be associated with 
mutations in Ddn
22
2014 Shimokawa et al in vitro delamanid does not inhibit or induce human cytochrome p450 
enzymes
28
Notes: Published preclinical delamanid data. *indicates abstract or conference presentation only.
Abbreviations: PK, pharmacokinetic; Mtb, Mycobacterium tuberculosis; BRM, bacterial reverse mutation.
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0.006 to 0.024 g/mL.19 Mtb may evade drug pressure by 
adopting intracellular sanctuary within macrophages. 
Delamanid’s intracellular bactericidal activity is similar to 
that of rifampicin.19 Among nontuberculous mycobacteria, 
delamanid has in vitro activity against M. kansasii and 
M. bovis but not M. avium, M. chelonae, M. abscessus, or 
M. fortuitum.19,25
In murine models of chronic TB, delamanid demonstrated 
a dose-dependent reduction in M. tuberculosis colony counts; 
it was equally effective in immunocompromised (nude 
BALB/c) mice, versus an inactive control. Drug doses associ-
ated with 95% reduction in colony-forming units (CFU) were 
0.625 mg/kg for delamanid, 3.5 mg/kg for rifampicin, 5 mg/kg 
for isoniazid, 160 mg/kg for ethambutol, and 40 mg/kg 
for streptomycin.19 To assess the activity of delamanid in 
combination with standard antituberculous agents, a 6-month a 
regimen of delamanid, rifampicin, and isoniazid was compared 
with standard quadruple therapy (rifampicin, isoniazid, pyrazi-
namide, and ethambutol) in a mouse model. After 6 months, 
0/6 mice in the delamanid group had detectable M. tuberculosis 
colonies, versus 4/5 in the standard treatment group.19
Pharmacokinetic considerations
Mechanisms of interindividual pharmacokinetic variability 
and drug-drug interactions for anti-TB compounds include 
induction or inhibition of metabolism via hepatic cytochrome 
p450 enzymes, or transportation of drugs via P-glycoprotein 
(P-gp), an important efflux pump that can influence intracel-
lular pharmacokinetics by transporting foreign substances out 
of cells. In preclinical studies, delamanid is highly (97%) 
protein bound and its metabolism is mediated primarily by 
plasma albumin. The hepatic enzymes CYP3A4, CYP1A1, 
CYP2D6, and CYP2E1 may be implicated to a lesser extent.20 
In animal models (dog, rat, mouse) it has an oral bioavail-
ability of 35%–60%.26,27
The effect of delamanid on human cytochrome p450 
enzymes has been studied in vitro with fresh human hepa-
tocytes and human liver microsomes. At concentrations 
less than 100 μmol/L (thought to be higher than that attain-
able in human liver), there was no effect of delamanid on 
CYP1A1/2, CYP2A6, CYP2B6, CYP2C8/9, CYP2C19, 
CYP2D6, CYP2E1, and CYP3A4.19 Similarly, in a separate 
study, four delamanid metabolites had no effect on these CYP 
enzymes at in vitro concentrations believed to be higher than 
that attainable in human liver.28
There are no peer-reviewed published data on the poten-
tial for pharmacokinetic drug interactions at the level of 
P-gp. However, the EMA assessment of delamanid reports 
that, in vitro, delamanid at 5 μM is neither a substrate nor an 
inhibitor for P-gp mediated transport. However, this concen-
tration is significantly lower than the estimated concentration 
of 74.8 μM in the intestinal lumen. Further post-authorization 
scrutiny of these studies is planned.20
Toxicity, mutagenicity, and teratogenicity
In animal studies, no toxic effects of delamanid on the central 
nervous or respiratory systems were found at concentrations 
18.5- or 3.2-fold higher than the maximum serum concentra-
tions expected in humans at a dose of 100 mg BD.20 Cardiac 
arrhythmias are of particular concern with second-line 
MDR-TB treatment as several key agents, including the fluo-
roquinolones (eg, moxifloxacin), clofazimine, and bedaquiline 
have ECG QTc-prolonging effects,29 raising concern about 
whether they can be coadministered. A degree of cardiac 
potassium channel (hERG channel) inhibition by delamanid 
was noted in vitro. In a canine model, there was no effect on 
ECG QTc interval in vivo after a single-dose but QTc interval 
prolongation was noted with repeated dosing.20 It is postu-
lated that plasma metabolites of delamanid, in particular the 
human metabolite DM-6705, may be primarily responsible for 
prolongation of QTc. This hypothesis is supported by the in 
vitro effect of DM-6705 and other delamanid metabolites on 
HEK-293 and CHO-K1 cells that express hERG channels.20
Similarly, hepatotoxicity is a significant concern with TB 
treatment as three of the four first-line agents (rifampicin, 
isoniazid and pyrazinamide) show significant hepatotoxicity. 
There are no published preclinical data on the effect of dela-
manid on the liver – deleterious or otherwise – though there 
is a suggestion from clinical data that delamanid may rarely 
have the potential for hepatotoxicity (see Adverse events and 
toxicity in Clinical data section). In mouse, rabbit, and rat 
models, delamanid has been shown to reduce the levels of 
clotting factors II, VII, IX, and X by inhibiting vitamin K1 
production, and increase prothrombin time (PT) and activated 
partial thromboplastin time (APTT).20
Older bicyclic nitroimidazoles with antimycobacterial 
activity, including CGI-17341, were not further developed 
because of concerns about mutagenicity. Delamanid has 
been shown to have low rates of mutagenicity in Salmo-
nella typhimurium and Escherichia coli bacteria by bacte-
rial reverse mutation (BRM) testing;19 similarly, in animal 
models (mouse and rat), the administration of delamanid up 
to 104 weeks was not carcinogenic.20
Animal data suggests that delamanid administration has 
the potential to be teratogenic; delamanid metabolites in rat 
models produced fetal abnormalities, though only exposure 
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to the drug at levels that were higher than would be expected 
clinically. Delamanid is also excreted in breast milk; in the 
rat, peak levels of delamanid in breast milk (C
max
) were 
fourfold higher than in the blood.20
Drug resistance
Like PA-824, delamanid is thought to require activation 
by mycobacterial F420-dependent deazaflavin-dependent 
nitroreductase (Ddn) coenzymes. Mutation in one of 
five coenzyme F420 genes, fgd, Rv3547, fbiA, fbiB, and 
fbiC has been proposed as the mechanism of resistance 
of delamanid.20,30 The in vitro spontaneous frequency of 
mutations conveying resistance to delamanid in one study 
was high and similar to that in isoniazid and pretomanid; 
rifampicin and moxifloxacin had lower rates.20 This sug-
gests that delamanid monotherapy would rapidly result in 
resistance, though this is an area where published data are 
lacking and ongoing evaluation of the genetic barrier to 
resistance of delamanid is necessary. There is not thought 
to be cross-resistance between delamanid and other antitu-
berculous agents.19
Clinical data
With favorable in vitro characteristics, delamanid progressed 
to clinical studies; Table 2 summarizes the published data 
from these studies, comprising Phase I pharmacokinetic and 
drug interaction studies, followed by Phase II clinical efficacy 
studies. The majority of Phase I data have not been published 
in peer-reviewed journals but are available in the EMA 
authorization report. The published trials were all carried out 
in accordance with the principles laid out in the declarations 
of Helsinki and national and local ethical guidelines.
Pharmacokinetics
Interindividual variability in the plasma concentrations 
of current first-line anti-TB drugs attained after standard 
weight-adjusted dosing is well described, and postulated to be 
responsible for some cases of treatment failure or generation 
of drug resistance.31,32 Debate about optimal dosing strategies 
in multidrug combinations are ongoing. Clinical information 
about the pharmacokinetic profile of new agents including 
delamanid is important.
The absolute oral bioavailability of delamanid has not 
been determined, but is thought to be 25%–47%.20 During 
dose escalation studies, administration of higher oral doses 
was associated with a less than proportional increase in 
plasma exposure.20,33 In contrast to some first-line anti-TB 
drugs (particularly rifampicin), delamanid exposure is 
increased by food, in particular by a high-fat meal. Exposure 
is approximately three times greater in a fed as opposed to 
fasted state.20,34 Differing absorption profiles between drugs 
may complicate coadministration in combination regimens. 
Table 2 Pharmacokinetic and clinical studies of delamanid
Study 
identifier
Clinical 
Phase
Type of study Number of 
participants
Reference
242-03-101 i First in man, single-dose, ascending dose, healthy subjects 56 20*
242-04-101 i Multiple dose, healthy subjects 52 20*
242-06-001 i Multiple dose escalation, healthy subjects 24 20*
242-05-001 i Single-dose escalation, healthy subjects 56 20*
242-05-101 i Multiple dose escalation, healthy subjects 104 20*
242-06-102 i Absorption, distribution, metabolism, excretion study with 
radiolabeled delamanid
6 20*
242-06-202 i Drug interaction (ethambutol and rifater), healthy subjects 55 20*
242-07-209 i Drug interaction (tenofovir, efavirenz, and ritonavir/lopinavir) 89 20,37
242-08-211 i Multiple dose PK; 1×, 2×, and 3× daily, healthy subjects 36 20*
242-08-212 i Drug interaction, efavirenz, healthy subjects 30 20,38
242-08-801 i Single-dose, food interaction, healthy subjects 48 20*
242-06-101 iia early bactericidal activity in uncomplicated, drug-sensitive, smear-
positive pulmonary TB vs standard quadruple therapy
54 33
242-07-204 iib Randomized, placebo-controlled trial of delamanid plus optimized 
background regimen for treatment of pulmonary MDR-TB to 
assess effect on sputum culture conversion at 2 months
481 49
242-08-208 ii Open-label continuation of Trial 204, for 6 months 213 50,51
242-10-116 Observational Observational data on 24-month follow-up of patients from Trial 
204 and 208
421 51
Notes: Published delamanid clinical studies. The majority of the Phase i pharmacokinetic and drug interaction data have not been published in a peer-reviewed journal but 
are available in the eMA authorization report, these data are indicated by an asterisk.
Abbreviations: PK, pharmacokinetic; MDR-TB, multidrug-resistant-tuberculosis; eMA, european Medicines Agency.
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Delamanid is extremely (99%) protein bound with a large 
apparent volume of distribution.20,34
Biotransformation and elimination
As stated above, delamanid is thought to be a prodrug that 
requires activation by mycobacterial F420-dependent Ddn 
coenzymes. Delamanid is eliminated directly from plasma 
with a half-life of 30–38 hours. It is not excreted in the 
urine.34 It is thought to be metabolized largely by plasma 
albumin; the full metabolic profile of delamanid has not been 
elucidated but the drug is thought to be largely converted 
to its primary metabolite, DM-6705 when amino groups 
in serum albumin react with the drug. DM-6705 is then 
broken down by hydrolysis and CYP3A4 to a number of 
other metabolites.20,34 Concentrations of these metabolites 
increase to steady-state over 6–10 weeks;34 they are thought 
to have poor anti-TB activity,20 but some metabolites may 
be primarily responsible for delamanid-associated toxicity. 
DM-6705, for example, is thought to be largely responsible 
for QTc prolongation. However, the full metabolic pathway 
of delamanid remains unknown.
Special populations
Hepatotoxicity is the most serious complication of current 
first-line anti-TB therapy, and the safety of new or alterna-
tive anti-TB drugs in patients with impaired liver function 
is an important clinical consideration.35 There are few data 
on the use of delamanid in patients with hepatic dysfunc-
tion and EMA advice is to avoid delamanid in patients with 
moderate to severe hepatic impairment. There is also a lack 
of data on the use of those over 65, in pediatric populations, 
and in HIV-infected individuals.20,34 This information will 
be important to establish the potential role of delamanid in 
vulnerable populations who run into difficulty with existing 
treatment options.
Dose adjustment for anti-TB drugs in renal impairment 
is also difficult and some second-line anti-TB drugs 
(particularly the injectable aminoglycosides) are associated 
with nephrotoxicity.36 Mild renal impairment (creatinine 
clearance 50–80 mL/min) is not thought to affect exposure 
to delamanid, and no dose adjustment is deemed necessary in 
mild-to-moderate renal impairment. It is not known if perito-
neal or hemodialysis removes delamanid from plasma.20,34
There are no data on the use of delamanid in pregnant 
women, and it is unknown if delamanid is excreted in human 
breast milk. The use of delamanid in pregnant or breastfeed-
ing women is therefore not recommended in the European 
license of delamanid.34
Potential for drug-drug interactions
The need for fewer drug-drug interactions has been noted 
as a desirable feature of new anti-TB agents. Table 3 shows 
available pharmacokinetic data from drug-drug interaction 
studies with delamanid. There is a clear interaction with the 
strong CYP3A4 inducer rifampicin, which reduced the 
exposure to delamanid by 47% in healthy volunteers.20 
There are no data with other strong enzyme inducers but 
this interaction would be expected to be similar, leading 
the EMA to recommend that coadministration of delamanid 
with strong CYP3A4 enzyme inducers is contraindicated.34 
This means that delamanid will only be suitable for future 
first-line regimens if rifampicin can be omitted. Given the 
established importance of rifampicin to prevent relapse in 
6-month anti-TB treatment, this is unlikely to be achieved 
in the near future; hence, the key initial role of delamanid is 
likely to remain in the management of MDR-TB.
Drug-drug interactions with ART are important when 
considering the role of delamanid for HIV-infected patients. 
In this regard, there was a modest increase in exposure to 
delamanid and its metabolites when coadministered with the 
Table 3 Pharmacokinetic data on drug-drug interactions of delamanid
Delamanid  
dose
Coadministered 
medication
Effect of delamanid on  
comedication
Effect of comedication on  
delamanid
Reference
200 mg OD ethambutol 1,100 mg steady-state plasma concentrations  
of ethambutol increased 25%
None 20
200 mg OD Rifampicin 300 mg None Delamanid AUC reduced by 47% 20
200 mg OD isoniazid 720 mg None Unchanged 20
200 mg OD Pyrazinamide 1,800 mg None Unchanged 20
100 mg BD Lopinavir/ritonavir 
400/100 mg BD
None Delamanid AUC increased by 22% 20,37
100 mg BD Tenofovir 300 mg OD None None 20,37
100 mg BD efavirenz 600 mg OD None None 20,37,38
Abbreviations: AUC, area under the plasma concentration–time curve; OD, once daily administration; BD, twice daily administration.
Therapeutics and Clinical Risk Management 2015:11submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
784
Lewis and Sloan
protease inhibitor lopinavir/ritonavir in healthy volunteer 
studies.20,37,38 This has potential implications for increased 
toxicity (in particular QTc prolongation); see Adverse events 
and toxicity section.
effectiveness in the treatment of MDR-TB
Definitive trials to ascertain the clinical efficacy of new 
anti-TB treatments are protracted and expensive because of 
the long duration of therapy and the need to incorporate post-
treatment relapse rates into study endpoints.39 As MDR-TB 
treatment continues for up to 2 years, the problem is great-
est with this form of the disease, and is compounded by 
inadequate surrogate markers to predict final outcome from 
shorter initial assessments.40 Furthermore, it is difficult to 
determine the effect of individual drugs during multidrug 
therapy. The standard approach is to begin by measuring the 
rate of decline in the bacterial load in sputum when single 
agents are administered for 7–14 days in Phase IIa studies 
(sometimes referred to as early bactericidal activity [EBA] 
studies). Preferred drug combinations are constructed for 
Phase IIb studies based on sputum culture conversion rates 
over a period of 8 weeks.41 Only regimens that perform well 
in Phase IIb studies should progress to Phase III clinical trials. 
Phase IIa and IIb data are available for delamanid but no 
Phase III studies have yet been reported.
The key Phase IIa study for delamanid was Trial 101 that 
evaluated four dosages of delamanid, administered orally for 
14 consecutive days. It recruited 54 smear-positive pulmonary 
TB patients aged 18–64 at three centers in South Africa, and 
randomized them to a dose of 100 mg, 200 mg, 300 mg, or 
400 mg of delamanid once daily, or standard quadruple therapy 
(rifampicin, isoniazid, pyrazinamide, ethambutol); the primary 
outcome was the fall in log
10
 CFU of Mtb per mL of sputum per 
day. Exclusion criteria were: serious underlying medical condi-
tions, electrocardiogram (ECG) abnormalities, HIV-infection 
with a CD4 count 350 cells/μL or use of ART, and patients 
with TB resistant to rifampicin on molecular testing.33
There was no statistically significant difference in the 
primary outcome between the four delamanid doses. The 
mean EBA across all delamanid groups was 0.04 log
10
 
CFU/mL/day, similar to previous values for rifabutin,42 
streptomycin,43 and amikacin,44 higher than pyrazinamide45 
but lower than quinolones, isoniazid, ethambutol, linezolid, 
and rifampicin.46–48
Phase IIb data on the efficacy of delamanid comes from 
three related studies on the same cohort of MDR-TB patients: 
Trial 204, Trial 208, and Observational Study 116. Details of 
these will be described in sequence but the chronological flow 
and relationships between them are shown in Figure 1.
Trial 204 provides the most robust data. It was a double-
blind, placebo-controlled, multicenter, multinational trial to 
assess the effect of delamanid on sputum culture conversion 
at 2 months in patients with pulmonary MDR-TB, alongside a 
World Health Organization (WHO)-recommended MDR-TB 
background treatment regimen. It took place at 17 centers in nine 
countries: the Philippines, Peru, Latvia, Estonia, People’s Repub-
lic of China, Japan, Korea, Egypt, and the United States.49,50
Participants were aged 18–64 with sputum culture-positive 
MDR-TB and chest radiographic findings consistent with 
TB. Exclusion criteria included HIV-infection with a CD4 
cell count 350 cells/μL or use of ART, ECG abnormalities, 
and co-therapy with antiarrhythmic agents or moxifloxacin. 
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Figure 1 Summary of the design and results of Phase iib and observational studies of delamanid therapy.
Notes: aDelamanid 100 mg, 200 mg, or placebo allocated by double-blind randomization; bdelamanid 100 mg or 200 mg allocated by treating physician. Data from Gler et al.49 
Copyright european Respiratory Society©. This material has not been reviewed by european Respiratory Society prior to release; therefore the european Respiratory Society 
may not be responsible for any errors, omissions or inaccuracies, or for any consequences arising there from, in the content. Reproduced with permission of the european 
Respiratory Society: Eur Respir J. 2013;41:1393–1400; published ahead of print September 27, 2012, doi:10.1183/09031936.00125812.51
Abbreviations: OBR, optimized background regimen; wHO, world Health Organization.
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Patients were randomized to delamanid 100 mg or 200 mg 
twice daily or placebo, administered alongside an optimized 
background regimen (OBR) selected in accordance with WHO 
guidelines. The primary outcome was the proportion of patients 
with sputum culture conversion in Mycobacterial Growth Indi-
cator Tube (MGIT) liquid broth media at 2 months. Secondary 
outcome measures included proportion of patients with sputum 
culture conversion on Lowenstein–Jensen (LJ) solid media and 
time to culture conversion on both media.49
A total of 611 patients were assessed for eligibility; 481 
were randomized into the study. A large proportion (90%) 
had received more than 30 days of TB therapy and almost 
40% had received second- or third-line drugs. The median 
age was 35, and 68% were men and 54% were from Asia. 
HIV positive patients were poorly represented; only four 
HIV positive people were enrolled.49
Table 4 shows that there was significantly higher sputum 
culture conversion in both delamanid groups compared to the 
group receiving placebo, and time to sputum culture conver-
sion was shorter in both groups receiving delamanid than in 
the group receiving placebo. These findings were consistent 
in both liquid and solid media.
Trial 208 was an open-label extension to Trial 204, con-
ducted at 14 of the 17 study sites. All Trial 204 participants 
were eligible to receive open-label delamanid 100 mg or 
200 mg twice daily. The choice of dosage rested with the treat-
ing physician, who remained blind to treatment allocation from 
Trial 204. There was a variable delay between completion of 
Trial 204 and commencement of Trial 208, dependent on local 
regulatory and ethics approval for Trial 208 at each site. This 
gap varied from 4 weeks to greater than 4 months, but was 
greater than 4 months for a third of participants.51 Background 
MDR-TB treatment was continued during this time.
Observational Study 116 was conducted at all 17 sites 
participating in Trial 204; and patients were followed up for 
2 years to assess final outcome. Data are available for 421 of 
the original 481 patients. Of these patients, 13.3% (56/421) 
had XDR-TB, and this subgroup is particularly interesting 
given the dearth of alternative treatment options for such 
patients. Participants in study 116 had received delamanid at 
a variable dose (100 mg or 200 mg or a combination of the 
two) for a variable length of time (between 0 and 8 months); 
some of this treatment was blinded, and some unblinded.51
Results of Trial 208 and Study 116 were published 
collectively.51 Patients who had been treated with either 
8 months (n=126) or 6 months (n=66) of delamanid were 
combined into a “long-term” treatment group. Patients who 
had received either 2 months (n=156) or 0 months (n=73) Ta
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of delamanid were combined into a “short-term” treatment 
group. The treatment outcomes for the two groups, defined 
as favorable (cured or completed treatment) or unfavorable 
(died, failed treatment, defaulted from treatment), are shown 
in Figure 2.
Among all MDR-TB and XDR-TB patients, there were 
more favorable outcomes in the “long-term” compared to the 
“short-term” delamanid treatment group (74.5% [143/192] vs 
55.0% [116/229], P0.001). There were also fewer deaths 
in the “long-term” group (1.0% [2/192] vs 8.3% [19/229], 
P0.001).51 In the XDR-TB subgroup analysis, there was a 
significant difference in mortality between the “short-term” 
and “long-term” groups for mortality (0% [0/44] vs 25.0% 
[3/12], P0.001).51
Adverse events and toxicity
In Trial 101, there were no serious adverse events and no 
patient discontinued the study drug due to toxicity. Minor 
QTc prolongation was thought to be related to delamanid in 
one patient; a detailed breakdown of adverse events is not 
presented in the published data.33
In Trial 204, over 90% of patients across all three treat-
ment arms (delamanid 100 mg, delamanid 200 mg, or pla-
cebo) experienced an adverse event, as shown in Table 5. 
Only the rates of QTc prolongation differed statistically sig-
nificantly between the three groups in pairwise comparisons; 
4% of patients in the placebo group experienced QTc prolon-
gation compared to 10% in the low-dose delamanid group, 
and 13% in the higher-dose delamanid group (P0.004 for 
evaluation of the dose–response trend).49
Patients with QTc prolongation in Trial 204 experienced 
a progressive increase from day 1–56. All QTc prolonga-
tions greater than 60 ms were associated with concomitant 
fluoroquinolone use,20 illustrating the potential hazard of 
overlapping toxicities in multidrug therapy. No cases of 
prolonged QTc interval resulted in syncope or arrhythmia 
and no patient stopped delamanid due to QTc prolongation. 
Reassuringly, this suggests that few ECG abnormalities are 
likely to result in clinical consequences, but ongoing vigi-
lance is clearly required.
Because delamanid metabolism involves serum albumin, 
administration of delamanid in the presence of hypoal-
buminemia has been associated with an increased risk of 
QTc prolongation. Similarly, as the delamanid metabolite 
DM-6705 is metabolized by CYP3A4, CYP3A4 inhibitors 
may exacerbate prolongation of the QTc interval.34
The number of patients discontinuing Trial 204 because 
of adverse effects was low and evenly distributed across the 
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Figure 2 Long-term outcome data on delamanid use from Trial 208 and Observational Study 116.
Notes: In the analysis of all MDR-TB and XDR-TB patients, significantly more patients had favorable outcomes in the “long-term” delamanid group than those in the “short-
term” group (P0.001). In the analysis of only XDR-TB patients, there were more favorable outcomes in the “long-term” group but the difference did not reach statistical 
significance, perhaps because of the small sample size. However, there were significantly fewer deaths in the “long-term group” (P0.001). Copyright european Respiratory 
Society©. This material has not been reviewed by european Respiratory Society prior to release; therefore the european Respiratory Society may not be responsible for any 
errors, omissions or inaccuracies, or for any consequences arising there from, in the content. Reproduced with permission of the european Respiratory Society: Eur Respir J. 
2013;41:1393–1400; published ahead of print September 27, 2012, doi:10.1183/09031936.00125812.51
Abbreviations: MDR-TB, multidrug-resistant-tuberculosis; XDR-TB, extensively drug-resistant-tuberculosis.
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three treatment groups; 4/161 (2.5%) for delamanid 100 mg 
BD (two due to psychiatric side effects, one due to dermato-
logic side effects, and one due to thrombocytopenia); 6/160 
(3.8%) for delamanid 200 mg BD (one due to leukopenia, 
three due to psychiatric side effects, one due to respiratory 
failure, and one due to dermatologic side effects), and 4/160 
(2.5%) for placebo, all due to dermatologic side effects.49
There were low rates of hepatotoxicity across all groups in 
Trial 204; 5/160 (3.1%) of patients in the placebo group, 4/161 
(3.1%) in the delamanid 100 mg BD group and 5/160 (3.1%) 
reported a hepatobiliary disorder, and none stopped the trial.
Adverse events in Trial 208 have not been presented, but 
the EMA authorization report contains some details. There 
was only one death in Trial 208, of a 25-year old man taking 
delamanid 100 mg BD who developed drug-induced liver 
injury and right-sided cardiac failure on the 9th day of the 
trial thought to be possibly related to delamanid. His liver 
injury resolved by day 27 upon stopping delamanid but he 
subsequently experienced respiratory failure and died on 
day 72.20 This lack of robust long-term toxicity data makes 
it difficult to comment on the long-term safety of delamanid; 
certainly data from Trial 204 and the favorable outcomes 
in Study 116 are reassuring, but Phase III data are awaited 
(see Forthcoming trials).
Forthcoming trials
While the accumulative Phase II and observational data are 
encouraging, Phase III data will be required before defini-
tive guidance on delamanid use is provided. A multicenter, 
double-blind Phase III placebo-controlled trial to assess the 
efficacy of 6 months of delamanid in addition to a back-
ground regimen for the treatment of MDR-TB is underway 
(NCT01424670).52 The trial protocol includes a subgroup 
of patients with HIV-infection, and results are expected in 
2017.
Trials are also underway in a pediatric population; a 
Phase I open-label trial to assess the pharmacokinetics of 
delamanid over 10 days in children (NCT01856634)53 and a 
Phase II 6-month safety, efficacy, and pharmacokinetic trial 
of delamanid in children with MDR-TB (NCT01859923).54 
The inclusion criteria for the Phase II trial allows for the 
inclusion of children with “probable TB,” which may better 
Table 5 Adverse events with delamanid therapy from Phase iib trial 204
Adverse event Delamanid, n (%) Placebo,  
n (%)  
(N=160)
100 mg BD  
(N=161)
200 mg BD 
(N=160)
Hematopoietic
Anemia 18 (11.2%) 10 (6.2%) 14 (8.8%)
Reticulocytosis 19 (11.8%) 20 (12.5%) 17 (10.6%)
Gastrointestinal
Nausea 58 (36.0%) 65 (40.6%) 53 (33.1%)
vomiting 48 (29.8%) 58 (36.2%) 44 (27.5%)
Upper abdominal pain 41 (25.5%) 36 (22.5%) 38 (23.8%)
Cardiovascular
Palpitations 13 (8.1%) 20 (12.5%) 10 (6.2%)
Prolonged QTc interval on eCG 16 (9.9%) 21 (13.1%) 6 (3.8%)
Respiratory
Hemoptysis 19 (11.8%) 15 (9.4%) 17 (10.6%)
Neurological
Headache 36 (22.4%) 41 (25.6%) 30 (18.8%)
Paresthesias 17 (10.6%) 20 (12.5%) 12 (7.5%)
Tremor 19 (11.8%) 16 (10.0%) 13 (8.1%)
insomnia 42 (26.1%) 51 (31.9%) 42 (26.2%)
General    
Tinnitus 16 (9.9%) 22 (13.8%) 12 (7.5%)
Asthenia 20 (12.4%) 27 (16.9%) 20 (12.5%)
Malaise 12 (7.5%) 16 (10.0%) 12 (7.5%)
Anorexia 23 (14.3%) 34 (21.2%) 24 (15.0%)
Hyperhidrosis 9 (5.6%) 17 (10.6%) 8 (5.0%)
Hyperuricemia 31 (19.3%) 38 (23.8%) 35 (21.9%)
Hypokalemia 20 (12.4%) 31 (19.4%) 24 (15.0%)
Notes: All adverse events with a frequency 10% are reported. With pairwise comparisons of the frequency of adverse events, only QT prolongation was significant 
(P=0.048 for comparison of 100 mg vs placebo and P=0.005 for the comparison of 200 mg vs placebo group by the Cochran–Mantel–Haenszel test). The Cochran–Armitage 
trend test also showed a dose–response trend in the incidence of QTc prolongation across the three dose groups (P=0.004). Data from Gler et al.49
Abbreviations: eCG, electrocardiogram; QTc, corrected QT interval; BD, twice daily administration.
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reflect the reality of clinical practice than results from studies 
including only bacteriologically confirmed disease.
The United States AIDS clinical trial group (ACTG) is 
planning a trial of the safety and efficacy of coadministration 
of bedaquiline and delamanid (ACTG A5343).
The place of delamanid in MDR-TB 
treatment
Two key questions dominate attempts to synthesize the 
available data on delamanid into a critique of its place in TB 
treatment: is there enough information to currently recom-
mend clinical prescription of this agent, and, if so, how should 
it be combined with other drugs for specific patient groups.
Assessment of when to license a new anti-TB drug is 
shaped by the tension between allowing sufficient time 
for thorough evaluation and providing potentially curative 
therapy to drug-resistant patients facing a poor prognosis 
with few other options. As with bedaquiline, the strength of 
Phase II and observational data has provisionally satisfied 
some regulators and, by January 2015, delamanid 100 mg BD 
had been cautiously approved for the treatment of MDR-TB 
by the EMA and Japanese MHWL.16 In 2014, the WHO also 
published interim guidance on delamanid for the treatment 
of drug-resistant TB.55
However, deficiencies in the available evidence must 
not be ignored. Although Trial 204 was well conducted, it 
was based on 2-month sputum culture conversion, which is 
at best an imperfect surrogate of long-term outcome56,57 and 
care is required when extrapolating from early microbio-
logical response to final clinical endpoints. This issue was 
recently illustrated by reports of inferiority to standard treat-
ment of shortened quinolone-based regimens (REMoxTB,58 
OFLATUB,59 and RIFAQUIN60) in the management of drug-
sensitive TB, despite promising rates of sputum culture con-
version at 2 months.61 The longer-term studies of delamanid 
(Trial 208 and 116) used pragmatic designs with method-
ological limitations; doses and durations of administration 
of the study drug were variable, and there was no blinding 
or randomization. All of these factors may have confounded 
the analyses that should be interpreted with caution.
For these reasons, current EMA approval is conditional 
on the manufacturer providing data from the Phase III trials 
detailed above. The WHO currently classifies delamanid as 
a Group 5 agent (defined by “limited data on efficacy and/or 
long-term safety”)62 and at present only endorses its use 
within strict criteria. These include proper patient inclu-
sion (ie, adults with highly drug-resistant disease including 
resistance to quinolones or injectables), incorporation of the 
new drug into recommended regimens,62 close monitoring, 
active pharmacovigilance, and informed patient consent.55 
This WHO conditional recommendation for delamanid’s 
use is similar to that for bedaquiline; there are some subtle 
differences in that the WHO recommends that patients with 
QTc 500 ms should not receive delamanid (a restriction 
that is not present for bedaquiline) and suggests that the addi-
tion of delamanid to a regimen may not be warranted if an 
appropriate regimen can be constructed from conventional 
second-line drugs.
The question of how to combine delamanid with other 
drugs will require new clinical trials, especially as the only 
ongoing delamanid Phase III trial is designed to assess the 
efficacy of delamanid alongside a standard background 
regimen for MDR-TB, rather than in novel combination 
therapies or alongside novel drugs. There are several 
other promising anti-TB agents in advanced development, 
including new compounds, repurposed drugs, and exist-
ing agents at nonstandard doses.3 A strategy to shorten 
MDR-TB therapy by combining seven or more drugs (the 
“Bangladesh regimen”63) is currently being compared to 
the conventional WHO approach in the STREAM trial. 
Although a second Phase of the STREAM trail plans to 
incorporate 6- or 9-month all-oral regimens including beda-
quiline, none of the proposed regimens include delamanid. 
As more data emerges, the contribution of individual drugs 
to a widening range of possible combinations needs to be 
systematically unraveled. Innovative study designs such 
as multiarm multistage trials may provide tools to rapidly 
compare multiple treatment regimens.64 Pharmacokinetic 
data on interactions between delamanid and other novel 
anti-TB agents are also needed.
In addition to selecting companion drugs, clinicians must 
decide whether new TB medicines are suitable for use in 
more complex patient groups. Despite case reports of suc-
cessful use,65 data to guide the use of delamanid in children 
are lacking. This reflects a wider lack of trials of therapeutic 
studies in pediatric TB,66 driven by the difficulty in assessing 
TB in children.67 Full EMA approval of delamanid is also 
dependent on the manufacturer providing results of Phase I 
and II pediatric studies.
A further concern is the lack of data on delamanid in 
HIV-infected individuals. As Trial 204 only enrolled four 
individuals with HIV and excluded those on ART, there is no 
outcome or pharmacokinetic data yet on this specific popula-
tion that represents a large proportion of TB cases in sub-
Saharan Africa. There is also very limited data on drug-drug 
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interactions with ART but preliminary data showing no 
interactions with tenofovir or efavirenz are reassuring.38
Finally, the place of delamanid in the programmatic 
management of MDR-TB will be driven by considerations of 
access and cost. Current licensing of delamanid is restricted 
to Europe and Japan and no licensing applications are in 
progress elsewhere, including countries with the highest 
MDR/XDR-TB burden. In the UK, a 40-tablet pack of 50 mg 
delamanid tablets costs £1,045.83,68 giving an approximate 
6-month cost of £18,000. This can be prohibitively expensive 
even in settings where a licensing is in place.
Off-license access to delamanid is restricted to compas-
sionate use programs but to date fewer than 20 patients have 
received the drug via this route, compared to several hundred 
patients who have received bedaquiline.69 Although bedaqui-
line is expensive, similar to delamanid in the UK, it has a 
differential pricing structure for low-income countries, and 
the manufacturer (Janssen), has recently announced a dona-
tion of 30,000 bedaquiline doses to low- and middle-income 
countries via the United States Agency for International 
Development (USAID). Innovative approaches to widening 
access to delamanid are also required to increase clinical 
knowledge and experience of this drug. This should occur 
within a careful framework of continuous efficacy and safety 
monitoring.
Conclusion
Delamanid is a promising agent that fulfills many target 
criteria for new TB drugs and may be particularly useful for 
the treatment of MDR-TB. It is administered orally and has 
bactericidal properties that may make it suitable in regimens 
designed to shorten treatment duration. Clinical efficacy 
data, while limited, are reassuring. It is well tolerated and, 
with the caveat of possible QTc prolongation, seems to have 
a favorable safety profile compared to existing second-line 
drugs. Long-term outcome data and greater experience of 
use in complex populations are required but there are con-
siderable grounds to be optimistic that delamanid represents 
an important addition to the currently limited management 
options for drug-resistant TB.
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